Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143546 | 0.83 | ALDH1A1 (0.44) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1170780 | 0.78 | ALDH1A1 (0.68) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14764482 | 0.77 | DAO (0.47) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29339069 | 0.76 | NPC1 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL34462940 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2106050 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL21496798 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9698797 | 0.75 | ALDH1A1 (0.55) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15088513 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7249651 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1PKMSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-3864015-B1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATEIVES | BAYER AG (DE) | 2023-05-10 | — | — | EP | disclosed |
| WO-2020233645-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | 浙江海正药业股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-20190263828-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170148996-A1 | ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC OPTOELECTRONIC DEVICES COMPRISING THE SAME | WUHAN TIANMA MICROELECTRONICS CO., LTD.SHANGHAI BRANCH (CN) | 2017-05-25 | — | — | US | disclosed |
| US-20170148996-A1 | ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC OPTOELECTRONIC DEVICES COMPRISING THE SAME | WUHAN TIANMA MICROELECTRONICS CO., LTD.SHANGHAI BRANCH (CN) | 2017-05-25 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004063169-A1 | HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-0842944-B1 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AG (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | ALDH1A1 1451/4885PKM 3542/4885SMN1; SMN2 1598/4885 |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | ALDH1A1 886/4885PKM 3136/4885SMN1; SMN2 4054/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885PKM 413/4885SMN1; SMN2 506/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885PKM 2591/4885SMN1; SMN2 4707/4885 |
| US-20190263828-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, UGT2B7 | ALDH1A1 583/4885PKM 3125/4885SMN1; SMN2 4499/4885 |
| US-20170148996-A1 | ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC OPTOELECTRONIC DEVICES COMPRISING THE SAME | OR10J3, PPOX, OR51E2 | ALDH1A1 625/4885PKM 753/4885SMN1; SMN2 4625/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | ALDH1A1 1494/4885PKM 4672/4885SMN1; SMN2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.